Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Publication

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Journal Paper/Review - Oct 22, 2015

Regan Meredith M, Sessa Fausto, Peg Cámara Vicente, Rodríguez Peralto José Luis, MacGrogan Gaëtan, Colleoni Marco, Goldhirsch Aron, Price Karen N, Coates Alan S, Gelber Richard D, Viale Giuseppe, Öhlschlegel Christian, Pizzolitto Stefano, Pagani Olivia, Francis Prudence A, Fleming Gini F, Walley Barbara A, Kammler Roswitha, Dell'Orto Patrizia, Russo Leila, Szőke János, Doimi Franco, Villani Laura, SOFT and TEXT Investigators and International Breast Cancer Study Group

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Coates, Alan S

Gelber, Richard D

Viale, Giuseppe

SOFT and TEXT Investigators and International Breast Cancer Study Group,